CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.
J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.
The Big Pharma paid $134 million to enter into the two partnerships but then dropped the projects after Voyager completed research activities.
